Session 1 – GDMT Essentials in the Real Life Setting
Chairs – Vijay Chopra and Camilla Hage
-
The 4 Pillars of GDMT Sequencing and Titration – Gianluigi Savarese
-
Managing GDMT and Hypotension – Michael Böhm
-
Implementing GDMT in the Frail and Elderly Patient – Cristiana Vitale
-
How to Manage GDMT in Advanced HF – Federica Guidetti
-
Panel Discussion
GDMT Implementation in HF – Bridging the Gap
-
Bridging the Implementation Gap in HF: Strategies to Improve Guideline Adherence – Biykem Bozkurt
-
In-hospital Initiation of GDMT: A Window of Opportunity – David Berg
Supported by unrestricted educational grant funding from AstraZeneca
Session 2 – Updates on Recent Trials in HF
Chairs – Stefan Anker and Amina Rakisheva
-
The VICTOR Trial – Faiez Zannad
-
FAIR-HF2 – Stefan Anker
-
DIGIT-HF – Udo Bavendiek
-
MAPLE-HCM – Pablo Garcia-Pavia
-
Panel Discussion
Beyond the Cornerstone: SGLT2 Inhibitors Shaping the Future of Heart Failure Care
Chairs – Stefan Anker and Maria Rosa Costanzo
-
SGLT2 Inhibitors in HF Prevention and Treatment: Clinical Trial Evidence – Giuseppe Rosano
-
Translating the Benefits of SGLT2 Inhibitors Therapy into Daily Care: Which Strategies to Improve Implementation – Shahzeb Khan
-
Looking Ahead in Heart Failure: SGLT2 Inhibitors and Combination Therapies – Maria Rosa Costanzo
Supported by an unrestricted educational grant from Boehringer Ingelheim
Session 3 – Obesity and Weight Management in HF
Chairs – Anu Lala-Trindade and Matthew Lee
-
Obesity and HF: Epidemiology and Mechanisms – Shahzeb Khan
-
Overview of Current Therapeutic Agents and Their Trial Results – Izza Shahid
-
New GLP1-based Drugs in the Pipeline: Oral, Triple Agonists and/or Once a Month – Dimitris Papamargaritis
-
Weight Loss Therapies and Body Composition Changes – Stefan Anker
-
Panel Discussion
REPLAY: GDMT Implementation in HF – Bridging the Gap
Bridging the Implementation Gap in HF: Strategies to Improve Guideline Adherence – Biykem Bozkurt
In-hospital Initiation of GDMT: A Window of Opportunity – David Berg
Supported by unrestricted educational grant funding from AstraZeneca
Session 4 – Managing Cardiomyopathy in HF
Chairs – Pedro Schwartzmann and Giuseppe Rosano
Cardiomyopathies and HF: What Should the Clinician Now Feature – Maurizio Pieroni
Differential Diagnosis – Arnt Kristen
Management of Cardiac Amyloidosis – Marianna Fontana
New Approaches in the Management of HCM – Ahmad Masri
Panel Discussion
Implementing Guidelines for ATTR-CM Diagnosis and Management: A Case-based Discussion
Olivier Lairez and Ahmad Masri
Early Recognition of ATTR-CM in HF Care
Implications of ATTR-CM for HF Management and Evolving Treatment Landscape
Supported by unrestricted educational grant funding from AstraZeneca
Cardiac Rhythm Devices in HFrEF ‒ Role, Timing, and Optimal Use in Contemporary Practice
Chair – Javed Butler
Speakers – Biykem Bozkurt, Christophe Leclercq, Wilfried Mullens, Andrea Russo, Gianluigi Savarese and Shelley Zieroth
The DIRECT HF educational programme is supported by Medtronic
Session 5 – Cardiac Rhythm Management in HF
Chairs – William Abraham and Mitja Lainscak
CRM Devices: Cornerstones of Patient-centred Management in HF – Biykem Bozkurt
Prevention of Sudden Arrhythmic Death in HFrEF – Carsten Israel
Role of Wearable Cardioverter-Defibrillators – David Duncker
CRT in HFrEF for Whom and When – Michael Böhm
Panel Discussion
REPLAY: Implementing Guidelines for ATTR-CM Diagnosis and Management: A Case-based Discussion
Olivier Lairez and Ahmad Masri
-
Early Recognition of ATTR-CM in HF Care
-
Implications of ATTR-CM for HF Management and Evolving Treatment Landscape
Supported by unrestricted educational grant funding from AstraZeneca
Session 6 – Devices in HF: Ready for Prime Time?!
Chair – Pedro Schwartzmann
Neuromodulation Therapy for HFrEF – JoAnn Lindenfeld
CCM: Benefits of Early Implementation – Marat Fudim
Interatrial Shunts – Michal Laufer-Perl
Sleep Apnoea – William Abraham
Panel Discussion
Session 7 – Managing HFpEF in 2025
Chairs – Oliver Schnell and Patricia Campbell
-
Diagnosis of HFpEF and Management Principles: The Basics – Cristina Gavina
-
Pillar 1 of HFpEF Therapy: SGLT2-inhibitor – Kieran Docherty
-
Pillar 2 of HFpEF Therapy: MRAs – Gerasimos Filippatos
-
The Experience in Primary Care – Ana Maria Cebrián Cuenca
-
Panel Discussion
Practical Aspects of NSMRA Use in HF
Muthiah Vaduganathan and Gianluigi Savarese
Supported by an unrestricted educational grant from Bayer
Session 8 – Enabling GDMT in HF
Chairs – David Sim and Ewa Jankowska
-
The Role of Potassium Binders – Francesca Musella
-
The Role of SGLT2i in Preventing Hyperkalemia – Giuseppe Rosano
-
Devices to Enable Drug Therapy – Gianluigi Savarese
-
Lessons Learned From REVOLUTION HF – Lisa Anderson
-
Panel Discussion
REPLAY: Beyond the Cornerstone: SGLT2 Inhibitors Shaping the Future of Heart Failure Care
Chairs – Stefan Anker and Maria Rosa Costanzo
-
SGLT2 Inhibitors in HF Prevention and Treatment: Clinical Trial Evidence – Giuseppe Rosano
-
Translating the Benefits of SGLT2 Inhibitors Therapy into Daily Care: Which Strategies to Improve Implementation – Shahzeb Khan
-
Looking Ahead in Heart Failure: SGLT2 Inhibitors and Combination Therapies – Maria Rosa Costanzo
Supported by an unrestricted educational grant from Boehringer Ingelheim
Session 9 – Improving Heart and Kidney Outcomes: The Role of MRAs
Chairs – Clara Inés Saldarriaga and Shelley Zieroth
Improving Outcomes for the Heart and Kidney – Biykem Bozkurt
The Role of Steroidal MRAs in HF – Joao Ferreira
Clinical Implications of the FINEARTS-HF – Scott Solomon
The Future of Heart and Kidney Therapies
Panel Discussion
SGLT2 Inhibitors in HF Management: The Present and the Future
Role of SGLT2 Inhibitors in the Management of HF Across the Ejection Fraction Spectrum – Shelley Zieroth
Practical Guidance for the Use of SGLT2 Inhibitors in Patients With HF Future Perspectives (Including Combination Therapies) – Maria Rosa Costanzo
Supported by an unrestricted educational grant from Boehringer Ingelheim
Session 10 – Valvular Heart Disease
Chairs – Marianna Adamo and Shahzeb Khan
-
Management of FMR in HF – Piotr Ponikowski
-
Management of TR in HF – Stephan Von Bardeleben
-
TAVI in HF Patients – Holger Thiele
-
Renal Denervation Therapy – Karl-Patrik Kresoja
-
Panel Discussion
Session 11 – Remote Monitoring and Team Approaches in the Management of HF
Chairs – JoAnn Lindenfeld and Marat Fudim
-
Latest Experience with Haemodynamic Monitoring – JoAnn Lindenfeld
-
New Device: From Voice Recognition to Lung Water Assessment – William Abraham
-
Reducing HF Hospitalisation by Disease Management Programme – Nicolas Girerd
-
Evaluation and Treatment of HF With Linq Sensors – Javed Butler
-
Panel Discussion
William Abraham
The Ohio State University, Columbus, US
Marianna Adamo
Civil Hospital of Brescia, Brescia, IT
Lisa Anderson
St George’s Hospital, London, UK
Stefan Anker
Charité Campus Virchow-Klinikum, Berlin, DE
Udo Bavendiek
Hannover Medical School, Hannover, DE
David Berg
Brigham and Women's Hospital, Boston, US
Michael Böhm
Saarland University Hospital, Homburg, DE
Biykem Bozkurt
Baylor College of Medicine, Texas, US
Javed Butler
University of Mississippi Medical Center, Jackson, US
Patricia Campbell
Craigavon Area Hospital, Craigavon, UK
Ana Maria Cebrián Cuenca
Centro de Salud San Antón, Murcia, ES
Vijay Chopra
Max Super Speciality Hospital, New Delhi, IN
Maria Rosa Costanzo
Midwest Cardiovascular Institute, Naperville, US
Kieran Docherty
University of Glasgow, Glasgow, UK
David Duncker
Hannover Medical School, Hannover, DE
Joao Ferreira
University of Porto, Porto, PT
Gerasimos Filippatos
National and Kapodistrian University of Athens, Athens, GR
Marianna Fontana
University College London, London, UK
Marat Fudim
Duke University, Durham, US
Pablo Garcia-Pavia
Hospital Universitario Puerta de Hierro Majadahonda, Madrid, ES
Cristina Gavina
University of Porto, Porto, PT
Nicolas Girerd
University Hospital of Nancy, Nancy, FR
Federica Guidetti
Karolinska Institute, Stockholm, SE
Camilla Hage
Karolinska University Hospital, Stockholm, SE
Clara Inés Saldarriaga
University of Antioquia, Medellín, CO
Carsten Israel
Bethel-Clinic, Bielefeld, DE
Ewa Jankowska
Wrocław Medical University, Wrocław, PL
Shahzeb Khan
Baylor Scott & White Health, Texas, US
Karl-Patrik Kresoja
University Medical Centre of the Johannes Gutenberg University, Mainz, DE
Arnt Kristen
University of Heidelberg, Heidelberg, DE
Mitja Lainscak
University of Ljubljana, Ljubljana, SI
Olivier Lairez
University Hospital of Toulouse, Toulouse, FR
Anu Lala-Trindade
The Mount Sinai Hospital, New York, US
Michal Laufer-Perl
Tel Aviv Sourasky Medical Center, Tel Aviv, IL
Christophe Leclercq
Hospital Pontchaillou of Rennes, Rennes, FR
JoAnn Lindenfeld
Vanderbilt University Medical Center, Tennessee, US
Ahmad Masri
Oregon Health & Science University Medical Group, Portland, US
Wilfried Mullens
Hospital Oost-Limburg (ZOL), Genk, BE
Francesca Musella
Santa Maria delle Grazie Hospital, Naples, IT
Dimitris Papamargaritis
University of Leicester, Leicester, UK
Maurizio Pieroni
University of Florence, Florence, IT
Ileana Piña
Thomas Jefferson University, Philadelphia, US
Piotr Ponikowski
Wrocław Medical University, Wrocław, PL
Amina Rakisheva
City Cardiology Center, Almaty, KZ
Giuseppe Rosano
St Georges Medical School, London, UK
Andrea Russo
Cooper Medical School of Rowan University, Camden, US
Gianluigi Savarese
Karolinska Institute, Stockholm, SE
Oliver Schnell
Diabetes Research Institute, Helmholtz Center, Munich, DE
Pedro Schwartzmann
Hospital Unimed, Ribeirao Preto, BR
Izza Shahid
Houston Methodist Academic Institute, Texas, US
David Sim
National Heart Centre Singapore, SG
Scott Solomon
Brigham and Women's Hospital, Boston, US
Holger Thiele
Heart Center Leipzig at University of Leipzig, Leipzig, DE
Muthiah Vaduganathan
Brigham and Women's Hospital, Boston, US
Cristiana Vitale
St George's University Hospital NHS Foundation Trust, London, UK
Stephan Von Bardeleben
University Medical Center of Mainz, Mainz, DE
Faiez Zannad
University of Lorraine, Vandoeuvre-Les-Nancy, FR
Shelley Zieroth
University of Manitoba, Winnipeg, CA
